Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Stock-based compensation expense, net of tax by Quarter
Stock-based compensation expense, net of tax ($M) ($M)
Vertex Pharmaceuticals Stock-based compensation expense, net of tax: $135M in Q2 2026, up 3.1% from a year earlier.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Note (Stock-based Compensation).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Stock-based compensation expense, net of tax ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 135 | +3.1% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 31, 2026 | 131 | +44.2% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 188 | +34.0% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2025 | Sep 30, 2025 | 147 | +22.8% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 131 | +78.0% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2025 | Mar 31, 2025 | 90.9 | -19.5% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2024 | Dec 31, 2024 | 141 | -6.4% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 120 | +27.9% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 73.5 | -16.5% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 113 | +38.0% | Form 10-Q (filed 2025-05-06) ↗ |
| Q4 2023 | Dec 31, 2023 | 150 | +118.5% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2023 | Sep 30, 2023 | 93.8 | -3.1% | Form 10-Q (filed 2024-11-05) ↗ |
| Q2 2023 | Jun 30, 2023 | 88 | +0.7% | Form 10-Q (filed 2024-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 81.8 | -13.3% | Form 10-Q (filed 2024-05-07) ↗ |
| Q4 2022 | Dec 31, 2022 | 68.7 | -37.2% | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2022 | Sep 30, 2022 | 96.8 | +18.9% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2022 | Jun 30, 2022 | 87.4 | +4.4% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2022 | Mar 31, 2022 | 94.3 | +12.4% | Form 10-Q (filed 2023-05-02) ↗ |
| Q4 2021 | Dec 31, 2021 | 109 | +35.4% | Form 10-K (filed 2024-02-15) ↗ |
| Q3 2021 | Sep 30, 2021 | 81.4 | +26.8% | Form 10-Q (filed 2022-10-28) ↗ |
| Q2 2021 | Jun 30, 2021 | 83.7 | -2.7% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 83.9 | +62.9% | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 80.8 | +46.9% | Form 10-K (filed 2023-02-10) ↗ |
| Q3 2020 | Sep 30, 2020 | 64.2 | +1.3% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2020 | Jun 30, 2020 | 86 | +35.2% | Form 10-Q (filed 2021-07-30) ↗ |
| Q1 2020 | Mar 31, 2020 | 51.5 | -5.2% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2019 | Dec 31, 2019 | 55 | -40.7% | Form 10-K (filed 2022-02-09) ↗ |
| Q3 2019 | Sep 30, 2019 | 63.4 | -28.5% | Form 10-Q (filed 2020-10-30) ↗ |
| Q2 2019 | Jun 30, 2019 | 63.6 | -27.3% | Form 10-Q (filed 2020-07-31) ↗ |
| Q1 2019 | Mar 31, 2019 | 54.3 | -3.6% | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2018 | Dec 31, 2018 | 92.7 | – | Form 10-K (filed 2021-02-11) ↗ |
| Q3 2018 | Sep 30, 2018 | 88.7 | – | Form 10-Q (filed 2019-10-31) ↗ |
| Q2 2018 | Jun 30, 2018 | 87.5 | – | Form 10-Q (filed 2019-08-01) ↗ |
| Q1 2018 | Mar 31, 2018 | 56.3 | – | Form 10-Q (filed 2019-05-01) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Stock-based compensation expense, net of tax ($M), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/sbc-net-tax
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.